Skip to main content
. 2022 Jan 28;22:118. doi: 10.1186/s12913-022-07495-4

Table 5.

The base-case analysis results (the lifetime analysis)

Strategy cost (PPP$) QALY Incremental Cost Incremental QALY ICUR (Incremental cost per QALY Gained) PPP$
Cost-Utility analysis Natalizumab 354,174.85 7.65 0 0
rituximab 58,307.93 7.77 − 295,867 0.125 dominant

ICER Incremental Cost-Effectiveness Ratio, QALY Quality Adjusted Life Year